NEW YORK (GenomeWeb) – CardioDx today announced the close of a $35 million financing round.

The funds will be used to expand the commercial use of Corus CAD and to support the company's development of other genomic tests for coronary artery disease, CardioDx said. Corus CAD is a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive CAD. 

Along with CardioDx's existing investors, Alberta Investment Management participated in the round.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Stat News reports that the head of IBM Watson Health is leaving her post.